Maven Bio

Maven Bio keeps the documents behind biopharma decisions current as the industry changes. Teams use Maven to build and maintain competitive views, asset screens, portfolio briefs, and target product profile benchmarks. They define the assets, markets, and questions they care about. Maven monitors new evidence against those priorities, delivers relevant signals, and updates their documents, with sources attached and the option to roll back changes. Maven's global live intelligence layer runs thousands of monitors across company and individual product websites, trade press, health technology assessment bodies, and patient advocacy groups. It brings changes from these distributed sources together with regulatory updates, trial records, financial disclosures, scientific publications, and conference abstracts. Maven links the evidence to the drugs, companies, and trials involved, tracks changes over time, and assesses new developments against each team's priorities. Teams can trace a signal or document update to its supporting evidence. The linked records provide context for interpreting a new finding and understanding which parts of an existing analysis need to change. That intelligence supports work in the Maven application and in the AI tools teams already use. Through connectors and an API, teams can combine Maven's evidence with their internal knowledge and workflows to power research, monitoring, and recurring deliverables. Maven serves business development, competitive intelligence, portfolio strategy, market access, and new product planning teams, as well as life sciences consultants and investors.